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 Oxidative stress has been linked to retinopathy of pre-
maturity (ROP) through several mechanisms related to oxy-
genation of retinal tissue [1-4]. The retina is believed to be
vulnerable to oxidative damage because of the abundance of
polyunsaturated fatty acids, the high metabolic rate, and rapid
rate of oxygen consumption of the photoreceptors, and possi-
bly from light-induced free radical formation [5-7]. In addi-
tion, the premature infant has reduced ability to scavenge re-
active oxidative species [8].
Both clinical and basic research support oxidative com-
pounds as playing a role in ROP. A meta-analysis of several
clinical studies that tested vitamin E to reduce ROP in infants
found a 52% overall reduction in the incidence of stage 3 ROP,
i.e. the stage with intravitreous neovascularization (IVNV).
The study was not able to evaluate later visual development
or complications of ROP [9]. In an oxygen-induced retinopa-
thy (OIR) model in rat, treatment with forms of vitamin E
[10,11] or manganese-superoxide dismutase [12] did not re-
duce pathologic IVNV but, compared to sham-injected con-
trols, did reduce the area of avascular retina, which, in human
disease has been associated with greater risk of poor visual
outcomes [13]. The avascular retina is proposed as the stimu-
lus for IVNV through the release of angiogenic growth fac-
tors, such as vascular endothelial growth factor (VEGF). Re-
ducing the size of avascular retina may help to reduce vision
loss in ROP, both by reducing the stimulus for IVNV and by
increasing the area of vascularized retina. However, despite
the lines of evidence supporting the role of oxidative stress in
ROP, to date, treatment of ROP with antioxidants has not been
widely accepted or successful [14]. This in part is because of
the complexities in studying oxidative pathways, the difficulty
in studying ROP in human infants, and the need for effective
yet safe treatments in the developing infant.
Although there are several models of OIR that have been
studied [4,15-22], the Penn 50/10 OIR model is most relevant
to what the human preterm infant with ROP currently experi-
nces [23], namely: (1) fluctuations in oxygen rather than con-
stant oxygen [4,24]; (2) a similarity in the extremes of oxygen
fluctuations that a preterm infant who developed severe ROP
experienced [23]; (3) retinal features similar to those of hu-
man ROP [25]. We proposed that the changes in tissue oxy-
genation associated with fluctuations in inspired oxygen [26]
might lead to an increase in oxidative substances particularly
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Purpose: To study the mechanisms of action of the antioxidants, n-acetylcysteine (NAC), and the nicotinamide adenine
dinucleotide phosphate (NAPDH) oxidase oxidase inhibitor, apocynin, on intravitreous neovascularization (IVNV), and
retinal avascularity in a rat model of retinopathy of prematurity (ROP).
Methods: Newborn rats exposed to oxygen-induced retinopathy underwent intraperitoneal (IP) injections of NAC (150
mg/kg) at post-natal day (p)2, p6, p10 (early NAC-treated), or p12 through p17 (late NAC-treated), apocynin (10 mg/kg)
from p12 through p17, or phosphate buffered saline (PBS; controls). Lipid hydroperoxide (LHP) was measured in early
NAC-treated oxygen-induced retinopathy (OIR) at p7, p14 and p18. Pups were placed in room air at p14. At p18, retinal
flat mounts were scored for IVNV and avascular/total retinal area, or retinas were assayed for cleaved caspase-3 and
vascular endothelial growth factor (VEGF) protein. In non-injected OIR pups, retinas were assayed for gp91phox. Cryosections
were stained with isolectin B4, cleaved caspase-3, CD68, CD31, gp91phox, neuron-glial antigen 2 (NG-2), or anti-glial
fibrillary acidic protein (GFAP) and visualized with confocal microscopy.
Results: LHP increased over time in retinas from OIR exposed pups in association with IVNV. Early NAC-treated retinas
had significantly reduced LHP compared to PBS-control at p18 (p<0.012). However, neither early nor late treatment with
NAC had an effect on IVNV or retinal avascularity. Although apocynin had no effect on IVNV, it reduced both avascular
retina (p=0.017) and retinal cleaved caspase-3 determined by western blot (p=0.021). In cryosections from OIR eyes,
cleaved caspase-3 positive cells co-labeled with some lectin-stained vessels, NG2 labeled cells, and with GFAP positive
cells in the inner nuclear layer. We found that the intravascular expression of gp91phox co-localized mostly with CD31 and
some CD68 positive cells.
Conclusions: Our results do not support the antioxidant properties of NAC as effective in reducing IVNV or avascular
retina in the 50/10 OIR rat model. Apocynin reduced avascularity and apoptosis in the OIR model perhaps through
pathways triggered by ROS generation but upstream from LHP production. Further study and consideration may be given
to apocynin or NAD(P)H oxidase inhibitors as adjunctive therapy for ROP to reduce the avascular retina.
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at the vulnerable junction of vascular and avascular retina
where the contrast in tissue oxygen levels is likely greatest.
Oxidative stress could then lead to several pathologic events
in ROP, including apoptosis of nascent intraretinal vascular-
ization or pathologic IVNV [27] by triggering signaling of
VEGF, inflammatory pathways, and TNF-α or other cytokines
[28]. To understand the role of oxidative compounds in ROP
development we used the 50/10 OIR model and analyzed for
lipid hydroperoxides (LHP), which are end-products of oxi-
dative stress and themselves causative of IVNV [29], and for
gp91phox, a subunit of NAD(P)H oxidase, which can increase
the release of reactive oxygen species and trigger many sig-
naling pathways including apoptotic and inflammatory path-
ways [30]. NAD(P)H oxidase can also increase VEGF expres-
sion, trigger signaling pathways causing endothelial migra-
tion [31], and has been associated with neovascularization in
some models [31,32]. Greater knowledge of the mechanisms
of oxidative compounds in a relevant model system may en-
able the development of directed and safe therapies for ROP.
METHODS
 All animals were cared for in accordance with the University
of North Carolina’s Institute for Laboratory Animal Research
(Guide for the Care and Use of Laboratory Animals) and the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
Model of oxygen induced retinopathy:  A bioactive gas
controller (Oxycycler; BioSpherix, New York, NY), which
regulates the atmosphere inside an incubator by injecting ei-
ther nitrogen or oxygen, was used to induce OIR in newborn
Sprague-Dawley rats (Charles River, Wilmington, MA) as
reported [33]. Within 24 h of birth, pups designated postnatal
day (p)0 and their mothers were placed into the incubator.
Oxygen was cycled between 50% and 10% every 24 h for 14
days, and then the pups were returned to room air for four
additional days (50/10 OIR model). Litters of 12 to 14 pups
were used in all experiments.
Inhibition of oxidative compounds:  We studied the ef-
fects of n-acetylcysteine (NAC, 150 mg/kg, Sigma, St. Louis,
MO), a water soluble antioxidant [34,35] in the OIR model.
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ent time points in two experimental groups. In the early group,
pups received IP injections at p2, p6, and p10 and in the later
groups daily from p12 to p17. The choice of drug regimen for
each group was based on reducing avascular retina (early NAC
treated group) or IVNV (late NAC treated group) without
greatly deviating from the oxygen cycling regimen, which can
affect model outcomes [25]. Controls received IP injections
of PBS. To inhibit NAD(P)H oxidase, apocynin (Sigma) di-
luted in PBS was injected IP (10 mg/kg) daily from p12 through
p17. Controls received IP injections of PBS at the same time
points.
Dissecting retinal tissue for flat mounting and
cryosections:  Pups were deeply anesthetized by IP injection
of ketamine (60 mg/kg) and xylazine (18 mg/kg). One ml of
0.5% paraformaldehyde (PFA, Sigma) in PBS was then di-
rectly perfused by intracardiac injection into the left ventricle
before euthanizing by intracardiac injection of pentobarbital
(80 mg/kg). Both eyes were enucleated and fixed in 2% PFA
for 2 h. The anterior segments were removed, and the retinas
with the ora serratas intact were carefully dissected and placed
into PBS, with care to remove the hyaloidal vessels and any
remaining vitreous. For flat mounts, each retina was then
placed onto a microscope slide and flattened by making four
incisions, each 90 ° apart, beginning at the ora serrata and
extending centrally from the equator, stopping short of the
optic nerve opening. For cryosections, eyes with anterior seg-
ments removed were put into 30% sucrose in PBS overnight.
Each eye was dried with filter paper, soaked in optimal cut-
ting temperature (O.C.T., Tissue-Tek, Torrance, CA) and kept
at -80 °C for future sectioning, immunostaining and analysis.
Tissue staining for flat mounts:  The flattened retinas were
permeabilized in ice-cold 70% (vol/vol) ethanol for 20 min
and then in PBS/1% Triton X-100 for 30 min. The retinas were
incubated with Alexa Fluor 568-conjugated Griffonia
simplicifolia (Bandeiraea) isolectin B4 (5 µg/ml; Invitrogen,
Carlsbad, CA) in PBS overnight at 4 °C for staining of the
vasculature. The retinas were rinsed three times in PBS and
mounted in PBS-glycerol (2:1, VectaShield; Vector Laborato-
ries), and the coverslips sealed with nail polish. Images of the
superficial blood vessel layers were captured with an inverted
microscope (TE2000U, Nikon, Tokyo Japan; Michael Hooker
Microscopy Facility, University of North Carolina, Chapel
Hill) and digitally stored for analysis. Digitized image sec-
t ons were stitched together into a montage of the retinal flat
mount using a commercial image-management software
(Adobe Photoshop 7.0: Adobe Systems, Mountain View, CA).
Counting clock hours of neovascularization:  Retinal im-
ages were randomized and divided into 12 clock hours of ap-
proximately equal area by using image-analysis software
(Photoshop 7.0; Adobe Systems, Mountain View, CA). Each
clock hour was then assessed by a masked examiner for the
presence of IVNV using an assessment technique adapted from
those used in animal models to quantify vessel tufts [36]. Each
retina received a score of 0 to 12, based on the number of
clock hours exhibiting IVNV.
Analysis of peripheral avascular areas:  Digitized im-
ages of the total retinal area and peripheral avascular areas
were measured using Image J software (NIH, Bethesda, MD).
The peripheral avascular area was expressed as a percentage
of the total retinal area.
Quantification of capillary density:  Central capillary den-
sity was quantified by summing capillary junctions within 4
equal square areas, each 0.16 mm2, in each of the 4 quadrants
of the vascularized retina and expressed as number of junc-
tions per 0.64 mm2 using ImageTool, Version 3 (University of
Texas, San Antonio, TX).
Tissue staining for cryosections:  Retinas frozen in O.C.T.
were cut into 10 µm sections and incubated in PBS/1% Triton
X-100 for 30 min. Some sections were incubated with Alexa
Fluor 568-conjugated Griffonia simplicifolia (Bandeiraea)
isolectin B4 (Invitrogen, Carlsbad, CA) in PBS for 30 min at
room temperature to stain the vasculature. After washing in
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PBS three times, sections were incubated for 30 min in 3%
normal goat serum to block non-specific binding. Anti-gp91phox
rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-rat CD68 mouse antibody (Serotec, Raleigh, NC), NG2
mouse antibody (Upstate, Charlottesville, VA), anti-rat CD31
mouse antibody (Serotec, Raleigh, NC) and cleaved caspase-
3 rabbit antibody (Cell Signaling Technology, Danvers, MA)
were used at a dilution of 1:100 in PBS and the sections incu-
bated for 60 min at room temperature. After three washes in
PBS, the sections were incubated for 20 min with a 1:500 di-
lution of a goat anti-mouse Alexa 568 secondary antibody
(Invitrogen) for CD68, NG2 and CD31 or goat anti-rabbit
Alexa 488 secondary antibody (Invitrogen) for cleaved
caspase-3 and gp91phox. Some sections were incubated with
Alexa Fluor 594-conjugated anti-glial fibrillary acidic protein
(GFAP) mouse antibody (Invitrogen) in PBS for 60 min at
room temperature. The sections were rinsed three times in PBS,
then incubated in a 1:5,000 dilution of Hoechst 33342
(Invitrogen) for 15 min and mounted in PBS-glycerol (2:1 with
VectaShield; Vector Laboratories, Burlingame, CA). Negative
controls used were samples incubated in conjugated second-
ary antibody only. The cover slips were sealed with nail pol-
ish. Images of the sections were captured with a scanning la-
ser confocal microscope (Leica SP2, Wetzlar, Germany) and
digitally stored for analysis.
Fresh tissue preparation:  Animals were euthanized with
an overdose of pentobarbital (80 mg/kg) injected IP. Eyes were
enucleated and the retinas were isolated under a dissecting
microscope in a similar fashion as used for flat mounting ex-
cept that the ora serratas were carefully removed. The tissue
was placed in HPLC-grade water for the LHP assay or RIPA
buffer (20 mM Tris base, 120 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 10% glycerol) with a protease inhibitor cocktail (1:100,
Sigma) for western blot and ELISA.
Determination of retinal lipid hydroperoxide:  Retinas
from pups in the OIR model injected IP with NAC at early
time points (p2, 6, 10) were measured for LHP at p7, p14, and
p18 and compared to PBS injected OIR pups at similar time
points. The LHP assay was performed according to the
manufacturer’s protocol (Lipid Hydroperoxide Assay kit,
Cayman Chemical, Ann Arbor, MI). Briefly, freshly dissected
unfixed retinal tissues in HPLC-grade water were homogenized
and the supernatant fractions from homogenized retinas cen-
trifuged at 13,000xg for 15 min at 4 °C were extracted with
0.25 ml of Extract R (Lipid Hydroperoxide Assay kit) satu-
rated methanol (methanol was degassed with nitrogen for at
least 30 min) and mixed by vortexing for 30 s. One milliliter
of degassed chloroform was added to each polypropylene tube
and mixed by vortexing for 30 s. The samples were centri-
fuged at 13,000xg for 5 min at 4 °C. The lower chloroform
phase was transferred to clean polypropylene tubes and stored
at -80 °C for future analysis. The standard LHP preparation
and chromogenic reaction assay was done according to the
manufacturer’s protocol. After color development, the samples
were pipetted into the wells of a 96-well glass plate and ab-
sorbance with measured with a FLUOstar OPTIMA (BMG
LABTECH, Offenburg, Germany) at 492 nm. The Bradford
assay (Bio-Rad, Hercules, CA) was performed to determine
the protein concentration of the cell lysate. LHP was expressed
in nmol LHP/mg total protein.
Protein extraction and western blot analysis:  Freshly dis-
sected unfixed retinal tissue immersed in RIPA buffer was
homogenized, and lysates were centrifuged at 13,000xg for
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Figure 1. Rat 50/10 oxygen-induced retinopathy model.  Rat retinal flat mounts stained with lectin at p14 (A) and p18 (B). Note peripheral
avascular areas of retina at p14 after 7 cycles of oxygen fluctuations (A) and IVNV at the junction of vascular and avascular retina at p18 after
4 days of RA exposure (B).
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15 min at 4 °C. The supernatants were collected, and the
Bradford assay was performed to determine protein concen-
tration of the cell lysate. The cell lysates were eluted with 6x
sample buffer (2.4 ml 1M Tris-HCl pH 6.8, 0.96g SDS, 4.8 ml
glycerol, 759 mg DTT, 4.8 mg bromophenol blue). 50 µg pro-
tein samples were separated by 7.5% or 15% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to a
polyvinylidene difluoride (PVDF) membrane, and reacted with
gp91phox antibody (1:1000, BD Transduction Laboratories, San
Diego, CA), cleaved caspase-3 antibody (1:1000, Cell Sig-
naling Technology, Danvers, MA) or VEGF antibody (1:1000,
Santa Cruz Biotechnology, Santa Cruz, CA) overnight, fol-
lowed by goat ant-rabbit HRP conjugated secondary (1:1000,
R&D Systems, Minneapolis, MN) for cleaved caspase-3 and
VEGF or goat anti-mouse HRP conjugated secondary anti-
body (CHEMICON, Temecula, CA) for gp91phox. β-actin
(1:10000, Abcam Cambridge, MA) was measured as a con-
trol. Visualization was performed with enhanced chemilumi-
nescence (Pierce, Rockford, IL). The signal intensity was quan-
tified from exposed films with analysis software (UN-SCAN-
IT, ver.6.1; Silk Scientific, Orem, UT).
Statistical analysis:  Data were analyzed with software
(SPSS version 14.0 Chicago, IL). Analysis of variance and t
tests were used to analyze parametric data such as avascular
area/total retinal area, capillary density, and normalized den-
sitometric values. Non-parametric data for IVNV score ob-
tained by the clock-hour method were analyzed with the Mann-
Whitney test. For each test, p<0.05 was considered signifi-
cant. All western blots had at least an N of 4.
RESULTS
Lipid hydroperoxides increased in 50/10 oxygen-induced ret-
inopathy model in association with intravitreous
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Figure 2. Lipid hydroperoxide in 50/10 oxygen-induced retinopathy
model.  Lipid hydroperoxide (LHP) levels in retinas assayed at post-
natal days 7, 14, or 18 (p7, p14, p18) from pups injected intraperito-
neally (IP) with n-acetylcysteine (NAC) or PBS at postnatal days p2,
p6, and p10 in the 50/10 oxygen-induced retinopathy (OIR) model.
Overall ANOVA, p<0.001, * p=0.012, Bonferroni post-hoc analysis
comparing p18 NAC to p18 PBS injected. (n=8 animals at p7 and 4
animals at p14 and p18).
Figure 3. Avascular retinal area and clock hours of intravitreous
neovascularization and capillary densities of n-acetylcysteine treated
pups.  A: Avascular retinal areas from pups exposed to 50/10 oxy-
gen-induced retinopathy (OIR) that had intraperitoneal (IP) injec-
tions of n-acetylcysteine (NAC) (n=6 each) at p2, p6, and p10 (early
treatment group) or once every 24 h from p12-p17 (n=6 each; late
treatment group) and assayed at p18 showed no significant differ-
ence compared to respective PBS controls (n=6 each; early, p=0.54;
late, p=0.19; Student t-test). B: Clock hours of intravitreous
neovascularization (IVNV) in retinas of OIR pups after IP injections
of NAC (n=6 each) at p2, p6, and p10 (early treatment group) or
once every 24 h from p12-p17 (n=6 each; late treatment group) and
assayed at p18 showed no significant difference compared to respec-
tive PBS controls (n=6 each; early, p=0.56; late, p=0.51; Mann-
Whitney test). C: Capillary densities did not differ between NAC- or
PBS- injected early treatment groups (p=0.88; n=6, Student t-test).
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neovascularization and avascular retina:  The 50/10 OIR
model developed peripheral avascular retina at p14, after 7
cycles of oxygen fluctuations, followed by IVNV at the junc-
tions of vascular and avascular retina at p18, as previously
published [37] (Figure 1). Since oxidative stress has been
linked to ROP, we wished to determine whether there was in-
creased production of oxidative compounds in the 50/10 OIR
model in association with IVNV occurrence. We measured
lipid hydroperoxide (LHP), end-products of oxidation, in
whole retinas from rat pups in the OIR model. LHP increased
in the model over time (Figure 2, PBS-injected pups) at the
time of maximal IVNV.
Inhibition of lipid hydroperoxides does not reduce avas-
cular retina or intravitreous neovascularization in 50/10 oxy-
gen-induced retinopathy model:  Since oxidative compounds
can trigger pathways of angiogenesis [30] or apoptosis [38]
directly or through release of inflammatory cytokines [39],
we inhibited LHP production using NAC and determined the
effect on avascular retina or IVNV. NAC was injected at two
different time points in separate regimens: early (with the ra-
tionale of reducing apoptosis and avascular retina) and later at
the time of greater LHP production (with the rationale of re-
ducing IVNV). NAC significantly reduced LHP in the OIR
model (Figure 2: ANOVA p<0.001, p7 (n=8); p14, and p18
[n=4 each]). However, despite significantly inhibiting the pro-
duction of LHP with the dose of NAC used, there was no sig-
nificant difference in peripheral avascular area (Figure 3A,
p=0.54 (early treatment), p=0.19 (late treatment), Student t-
Test, n=6) or IVNV (Figure 3B, p=0.56 (early treatment), p=
0.51 (late treatment), Mann-Whitney test, n=6) from early
NAC-treated groups or late NAC-treated groups compared to
respective PBS controls. In addition, there was no difference
in capillary densities between NAC- and PBS-injected retinas
from the early treatment group (Figure 3C, p=0.88, n=6, Stu-
dent t-test). At p18, there was no difference in the amount of
VEGF protein (Figure 4, p=0.82, n=4, Student t-test), or
cleaved caspase-3 (Figure 5, p=0.74, n=4, Student t-test) mea-
sured in retinas from late NAC treated or PBS treated pups by
western blot.
gp91phox expression in 50/10 oxygen-induced retinopathy
model:  We also studied a gp91phox (NOX2) containing
NAD(P)H oxidase. NOX family members are transmembrane
proteins that transport electrons across biological membranes
to reduce oxygen and are selective for NADPH over NADH.
gp91phox is one of the most studied of the NOX family mem-
bers. Phagocytes and endothelial cells can express gp91phox
and endothelial cell NAD(P)H oxidase can trigger pathways
involving endothelial cell migration and VEGF expression,
as well as inflammatory, apoptotic, and oxidative pathways
[30,31,39]. Because these pathways may be important in re-
ducing retinal avascularity or IVNV independent of LHP for-
mation, we measured gp91phox at relevant time points around
the transition from avascular retina (p14) to IVNV (p18) in
the 50/10 OIR model. The variation in gp91phox protein/actin
in whole retinas was not significant at time points measured
(Figure 6, p=0.99, ANOVA, n=at least 4 per time point).
Apocynin reduces retinal avascularity but not intravitre-
ous neovascularization:  Although inhibition of LHP with NAC
did not reduce retinal avascularity or IVNV, LHP increased in
he 50/10 OIR model in association with these features.
NAD(P)H oxidase can cause a release of reactive oxygen spe-
cies (ROS), which ultimately can lead to the end products,
LHP. Through ROS generated prior to LHP production,
NAD(P)H oxidase can also cause apoptosis, inflammation,
and changes in cell proliferation. In addition, it can cause
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Figure 4. Western blots of vascular endothelial growth factor from
p18 retinas of rats Injected with n-acetylcysteine, apocynin, or phos-
phate buffered saline.  Western blot of vascular endothelial growth
factor (VEGF) in oxygen-induced retinopathy pups treated with PBS,
apocynin, and n-acetylcysteine (NAC; intraperitoneal injections once
every 24 h from p12 to p17) showed no difference in VEGF protein
from retinas analyzed at p18 (p=0.82, Student t-test, n=4, phosphate
buffered saline (PBS) versus NAC; p=0.201, Student t-test, n=4, PBS
versus apocynin). Overall ANOVA comparing three groups p=0.3120.
Figure 5. Western blot of cleaved caspase-3 from p18 retinas of pups
injected with n-acetylcysteine or phosphate buffered saline.  West-
ern blot of cleaved caspase-3 showed no difference in retinas from
OIR pups that received intraperitoneal injections once every 24 h
from p12 to p17 of n-acetylcysteine versus phosphate buffered sa-
line (p=0.74, Student t-test, n=4).
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apoptosis more directly by activation of proapoptotic signal-
ing proteins [30]. Therefore, we determined whether inhibi-
tion of NAD(P)H oxidase would reduce IVNV or avascular
retina perhaps through a mechanism parallel to or upstream
from LHP production. Based on our data of increased oxida-
tive compounds at p14 and p18 (Figure 1), we injected the
NAD(P)H oxidase inhibitor, apocynin, IP daily from p12 to
p17, similar to the NAC late-treatment group. We found that
apocynin-injected groups had significantly smaller peripheral
avascular areas compared to controls (Figure 7A, Student’s t-
test p=0.017, n=11). However, there was no significant differ-
ence in IVNV score (Figure 7B, p=0.26, Mann Whitney test,
n=11).
Apocynin inhibits apoptosis but not vascular endothelial
growth factor expression:  Since the avascular retina was re-
duced, we wished to determine whether angiogenic or
apoptotic pathways were affected by apocynin. Therefore, we
measured VEGF expression, which is a survival factor for
endothelial cells and neurons, and cleaved caspase-3, a cys-
teine protease expressed during apoptosis, in whole retinas
from PBS and apocynin treated pups. There was no signifi-
cant difference in VEGF protein measured at p18 in apocynin
injected groups compared to PBS injected determined by west-
ern blot (Figure 4; p=0.77, n=4). There was also no difference
in capillary density of newly vascularized retinas between
apocynin and PBS treated groups (Figure 7C, p=0.37, Stu-
dent t-Test, n=6). However, apocynin significantly inhibited
cleaved caspase-3 determined by western blot of whole reti-
nas as compared to controls at p14 (Figure 8A, Student’s t-
test p=0.021, n=4) but not at p18 (Figure 8B, Student t-test,
p=0.78, n=4).
50/10 OIR Model shows apoptosis of endothelial cells,
pericytes, and glial cells and expression of endothelial cell
gp91phox:  To characterize the cells that were apoptotic in the
OIR model, we examined cryosections of p18 eyes from 50/
10 OIR control eyes that were co-labeled with cleaved caspase-
3 and lectin; CD68, lectin and cleaved caspase-3; lectin, NG-
2, and cleaved caspase-3; or glial fibrillary acidic protein
(GFAP) and cleaved caspase-3 using confocal microscopy.
Cleaved caspase-3 positive cells were adjacent to lectin stained
vessels (Figure 9A, arrow) and co-stained with NG-2 suggest-
ing pericyte involvement (Figure 10). In some cases, lectin
co-stained with cleaved caspase-3 (Figure 9A, arrowhead) pro-
viding evidence that some endothelial cells were apoptotic.
CD68 labeling was greatest in the regions of retinal vascula-
ture and less in the regions of avascular retina. CD68 stained
cells and processes aligned with blood vessels in the inner
nuclear layer adjacent to the outer plexiform layer and at the
interface with the vitreous (Figure 11). Only rarely were CD68
positive cells co-labeled with cleaved caspase-3 (Figure 9B,
rrowhead). Few GFAP positive nuclei co-stained with cleaved
caspase-3 (Figure 9C, arrowhead). These results suggest that
apoptosis occurred mainly in endothelial cells, perivascular
cells representing pericytes, and possibly glia in the 50/10 OIR
model at p18. These data, though sensitive, are qualitative and
are viewed with the knowledge that apoptotic cells may lose
cell markers making it difficult to identify them with immu-
nohistochemical stains.
To determine what cells stained for gp91phox, we qualita-
tively analyzed cryosections of retinas from control OIR rat
retinas at p18. gp91phox cells co-labeled with CD68 (Figure
11) suggesting a leukocyte origin. However, most of the stain-
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Figure 6. p91phox expression by west-
ern blot in oxygen-induced retinopa-
thy retinas.  P14 pups were
euthanized immediately after re-
moval from hypoxia (p14), after 2
h of room air (p14+2), after 6 h of
room air (p14+6) or at p15, p16,
p17, p18. Values are expressed as
gp91phox over β-actin (n=at least 4
samples per group). gp91phox expres-
sion did not significantly change
over the time points measured
(p=0.99, ANOVA, n=at least 4/time
point).
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ing at the time point analyzed was localized within the ves-
sels. We co-labeled sections with CD31 or NG2 and gp91phox
and found that gp91phox co-localized mostly with CD31+ cells
(Figure 9D) and not with NG2+ pericytes (Figure 12), sug-
gesting that endothelial cells account for a large proportion of
the intravascular gp91phox expression. There did not appear to
be a difference in gp91phox staining within intraretinal blood
vessels located at the junction of vascular and avascular retina
at p18 in OIR compared with blood vessels more centrally
located.
DISCUSSION
 Evidence supports oxidative compounds play a role in ROP
[1-4]. The retina is susceptible to oxidative damage [6] given
its high metabolic rate and rapid rate of oxygen consumption
[5]. In addition, the premature infant has a reduced ability to
scavenge reactive oxidative species [8], increasing its vulner-
ability to oxidative stress. We found that LHP were signifi-
c ntly increased in the 50/10 OIR model at time points corre-
sponding to IVNV. LHP induce a cascade of interacting an-
giogenic cytokines [28] such as VEGF, TNF-α, IL-1α, PDGF,
and TGF-β. When LHP are injected into the rabbit vitreous,
they can cause IVNV [28]. Yet, our data suggest that other
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Figure 7. Avascular retinal area and clock hours of intravitreous
neovascularization and capillary densities of apocynin treated pups.
A: Percent avascular retinal area in oxygen-induced retinopathy (OIR)
after intraperitoneal (IP) injections with apocynin once every 24 h
from p12 to p17 and assayed at p18 was significantly reduced com-
pared to phosphate buffered saline (PBS) injected pups (* p=0.017,
Student’s t-test; n=11 retinas each). B: Clock hours of intravitreous
neovascularization (IVNV) in OIR retinas after IP injections with
apocynin once every 24 h from p12 to p17 and assayed at p18 were
not significantly different to PBS injected pups (p=0.26; Mann-
Whitney test, n=11). C: At p18, capillary densities did not differ be-
tween apocynin and PBS injected treatment groups. (p=0.37; Stu-
dent t-test, n=6).
Figure 8. Cleaved caspase-3 in retinas from apocynin treated pups.
A: Cleaved caspase-3 expression in the retinas of OIR after IP injec-
tion with apocynin on p12 and p13 and assayed on p14 was signifi-
cantly decreased compared to retinas from PBS injected pups
(p=0.021, Student’s t-test, n=4). B: However, no significant differ-
ence in cleaved caspase-3 expression was measured in retinas of pups
injected with apocynin every 24 h from p12 to 17 and assayed on
p18 compared to PBS injected pups (p=0.78, Student t-test, n=4).
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pathways may play a role in the pathogenesis of ROP and that
endogenous LHP themselves are not causative of IVNV in the
rat OIR model.
NAC has reducing and antioxidant properties by acting





O2- [40,41]. It also restores the pool of intracellular reduced
glutathione [42] and is an inhibitor of NF-κ B and inflamma-
tory cytokines [43,44]. We used a dose of NAC in the range
used in studies in rats and mice [45-47], and found that the
dose significantly reduced LHP in the 50/10 OIR model com-
pared to PBS control. However, neither early nor late NAC-
treatment groups had significantly reduced avascularity or re-
duced clock hours of IVNV compared to PBS-injected OIR
groups. The clinical efficacy of NAC has not been universally
established in vivo. In a clinical trial testing a low dose of
NAC (16-32 mg/kg/day) given to premature infants under 1000
g birthweight for the first 6 days after birth, there was no sig-
nificant difference in survival, body weight gain, respiratory
disease, or ROP [48]. Although the authors suggested that too
short an intervention was one possible reason for failure, we
also did not find an effect using two different treatment regi-
mens and with a higher dose of NAC that we had evidence
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Figure 9. Cryosection of p18 oxygen-induced retinopathy eye from pups after intraperitoneal injection with phosphate buffered saline from
p12 to p17.  A: Cleaved caspase-3+ cells (green) were adjacent to lectin stained vessels (red), suggesting possible pericyte or leukocyte
apoptosis, whereas lectin also co-stained with cleaved caspase-3 (arrowhead), supporting apoptosis of endothelial cells. B: Rare CD68+
stained cells (red) co-labeled with cleaved caspase-3 (Green) (arrowhead). C: Cleaved caspase-3+ nuclei in inner nuclear layer (INL) and
ganglion cell layer (GCL, green), some of which only rarely co-labeled with anti-glial fibrillary acidic protein (GFAP, red arrowhe d), sug-
gesting apoptosis of glia. D: Mostly CD31+ endothelial cells (red) co-localized with gp91phox (green) in vessels. ONL represents outer nuclear
layer; IPL represents inner plexiform layer.
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inhibited endogenous LHP production in the retina. In a re-
view of the efficacy of NAC as a treatment of chronic ob-
structive pulmonary disease, the authors discussed the discor-
dance in the effects of NAC in in vitro and in vivo studies
[49]. Although the reasons remain mostly unknown, NAC can
have different effects, particularly as an anti-inflammatory
agent, based on dose and cell type and may explain why ben-
eficial effects in vitro are not always translated into the in vivo
condition [49]. We found that NAC reduced LHP generation
most likely through its effects as an anti-oxidant. However,
NAD(P)H oxidase can cause oxidative stress induced apoptosis
or inflammation through pathways that are upstream from the
generation of LHP, and this may account for our findings.
Armstrong et al reported that exogenously injected LHP into
rabbit vitreous caused a cascade of inflammatory and angio-
genic factors within the retina in a time course associated with
the development of IVNV [26,50]. However, there may be
differences in tissue responses to exogenously delivered LHP
into vitreous from that generated endogenously within the
retina. In addition, a recent study of gene expression profiles
showed that colon cells exposed to endogenously generated
lipid peroxides could mount a DNA repair response whereas
those exposed to exogenously administered lipid peroxides
could not [51].
NAD(P)H oxidase provides a major source of superox-
ide radicals during hyperoxia [52] and hypoxia [39] and can
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Figure 10. Cryosection of p18 oxygen-induced retinopathy eye from pups after intraperitoneal injection with phosphate buffered saline from
p12 to p17.  Labeling with NG2 (A, blue), cleaved caspase-3 (B, green), and lectin (C, red). Some NG2 labeled cells co-localized with cleaved
caspase-3 (aqua, D) suggesting pericyte apoptosis. GCL represents ganglion cell layer; INL represents inner nuclear layer; IPL represents
inner plexiform layer.
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trigger pathways leading to apoptosis, VEGF expression, en-
dothelial cell migration, or inflammation [30,39]. Apocynin
specifically blocks the activity of NAD(P)H oxidase by inter-
fering with the assembly of the cytosolic NAD(P)H oxidase
components (p40phox, p47phox, p67phox) with the membra-
nous components gp91phox and p22phox [39,53,54]. It is also
used as an anti-inflammatory drug [55,56]. We first investi-
gated whether there was a peak expression of gp91phox protein
in the 50/10 rat OIR model. We found a low expression of
gp91phox that did not change significantly from p13 to p18 in
the OIR model. However, by immunohistochemistry, we found
cells stained for gp91phox antibody within blood vessels in lo-
cations of endothelial cells and some leukocytes. Pericytes in
vitro have been suggested to express certain homologs of
NAD(P)H oxidase [30]. However, the location of gp91phox
expression in cryosections of eyes from the OIR model was
mainly within CD31 stained endothelial cells and not within
NG2 stained pericytes. Some cells may be leukocytes based
on co-staining with CD68. Other investigators found higher
gp91phox expression in the mouse OIR model than what we
found in the rat 50/10 OIR model [32]. This difference may
represent differences between species or the model. The mouse
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Figure 11. Cryosection of p18 oxygen-induced retinopathy eye from pups after intraperitoneal injections with phosphate buffered saline f om
p12 to p17.  Labeling with lectin (A, red), gp91phox (B, green), and CD68 (C, blue). gp91phox co-labeled CD68 cells (D, light blue cells). CD68
stained leukocytes aligned with lectin stained vessels (D, magenta).
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OIR model exposes mice to higher and constant oxygen
stresses (75% O
2
 for 5 days) [17], whereas the 50/10 OIR model
exposes pups to less extreme hyperoxia and not at a constant
level, more consistent with blood oxygen levels experienced
by preterm infants today. In addition, even a relevant change
in protein expression within a small population of cells might
have been missed by western blot analysis of a whole retina.
Apocynin injected groups had significantly reduced pe-
ripheral retinal avascular areas compared to PBS groups. How-
ever, IVNV scores did not differ between apocynin and PBS-
injected groups. We did not find a difference in VEGF expres-
sion determined by ELISA of tissue samples in apocynin-
treated and PBS controls, nor a change in capillary density of
newly formed vessels within the vascularized retinas. These
findings did not support altered VEGF production as the
mechanism for the apocynin effect although a significant
change in VEGF expression in a limited number of cells could
be missed in analysis of an entire retina by western blot. In
ddition, the time of assay may have missed a change in VEGF
expression. In contrast, by western blot, cleaved caspase-3 was
r duced significantly in apocynin-injected groups compared
to PBS-injected groups at p14, showing a reduction in
poptosis in association with reduced avascular retina.
NAD(P)H oxidase can cause apoptosis indirectly through the
release of reactive oxygen species or more directly by activat-
ing proapoptotic signaling proteins [30]. The reduction in avas-
cular retina we found from apocynin may be through more
direct effects on apoptosis signaling or through apocynin’s
e fects on inflammatory pathways given the variable in vivo
r sponses of NAC as an anti-inflammatory agent [49].
We also stained cryosections for CD68 since NAD(P)H
oxidase can trigger inflammatory pathways and found that
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Figure 12. Cryosection of p18 oxygen-induced retinopathy eye from pups after intraperitoneal injections with phosphate buffered saline f om
p12 to p17.  gp91phox localization (A, green) resided mainly inside of the /lectin stained (red) /vessel wall (z-series, B), suggesting that
endothelial cells, and not NG-2 positive pericytes (red), express NAD(P)H oxidase in the oxygen-induced retinopathy model.
850
CD68 labeled cells were co-labeled with gp91phox and rarely
with cleaved caspase-3. CD68 labeled leukocytes aligned with
lectin-stained vessels in vascularized retina. We did not find
CD68 positive cells in the avascular retina where there were
no endothelial cells or blood vessels, supporting other studies
that show macrophages in newly vascularized retina to be in-
volved in vascularization and remodeling of vessels [57-59].
We found that some lectin stained blood vessels and NG-2
positive perivascular cells co-labeled with cleaved caspase-3
providing support that endothelial cells [60] and pericytes were
apoptotic. We also found a number of cleaved caspase-3+ cell
nuclei in the inner nuclear and ganglion cell layers, some of
which co-labeled with GFAP, likely representing glia. The
immunohistochemical studies provided important qualitative
co-labeling data that complements the western blot data.
We propose that oxygen fluctuations, such as what pre-
mature infants experience [23], cause cells within newly
formed blood vessels, mostly endothelial cells and some in-
travascular leukocytes to express NAD(P)H oxidase, which
then leads to increased reactive oxygen species [39]. Through
NAD(P)H oxidase activation and either indirectly through ROS
generation, inflammatory cytokine production, or more directly
by activating proapoptotic signaling proteins [30], endothe-
lial cell and pericyte apoptosis is increased contributing to the
avascular retina. In addition, apoptosis of some inner nuclear
layer Mueller cells or astrocytes may reduce the production of
VEGF, which is necessary in the survival of nascent blood
vessels [58]. Investigators have reported that glia, including
astrocytes [61] in development and Mueller cells in other OIR
models, express VEGF. Although we did not find a difference
in VEGF expression in retinas from apocynin- or PBS-treated
pups, again a significant difference in a few cells may have
been missed in whole retina analyses.
This study provides support that induced NAD(P)H oxi-
dase appears detrimental to newly developed blood vessels
within the retina and involves a pathway leading to apoptosis
that is associated with avascularity. In the OIR model, endot-
helial cells express gp91phox and these cells and perivascular
NG2 staining pericytes also become apoptotic. Since NAC
inhibits most oxidative compounds but did not have an effect
on IVNV or avascular retina in the model, our data suggest
that the cause of apoptosis may involve a connected but sepa-
rate pathway from oxidative stress. The anti-inflammatory
properties of NAC in vivo have not been consistent. Perhaps,
NAD(P)H oxidase is acting through its inflammatory effects
or more direct effects on proapoptotic signaling. Reduction of
the retinal avascularity may lead to better outcomes by in-
creasing the areas of retinal development and reducing the
stimulus for IVNV in ROP.
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